Daily oral etoposide in patients with heavily pretreated metastatic breast cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 5, 1998, Pages 442-446

  Pusztai, L ^a   Walters, R S ^a   Valero, V ^a   Theriault, R L ^a   Hortobagyi, G N ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Metastatic breast cancer; Oral etoposide

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NAVELBINE;

ADULT; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; BREAST METASTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; SALVAGE THERAPY;

EID: 0031755080     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199810000-00004     Document Type: Article

References (27)

1. Hortobagyi GN. Multidisciplinary management of advanced primary and metastatic breast cancer. Cancer 1994;74:416-23.
2. Honig SF. Treatment of metastatic disease, hormonal therapy and chemotherapy. In: Harris JR, Lippman ME, Morrow M, Hellman S, eds. Diseases of the breast. Philadelphia: Lippincott-Raven, 1996:669-727.
3. Tomiak E, Piccart M, Mignolet F, et al. Characterisation of complete responders to chemotherapy for advanced breast cancer: a retrospective EORTC Breast Group study. Eur J Cancer 1996;32:1876-87.
4. Greenberg PAC, Hortobagyi GN, Smith TL, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:2197-205.
5. Holmes F, Walters RS, Theriault RL, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991;83:1797-803.
6. Terenziani M, Demicheli R, Brambilla C, et al. Vinorelbine: an active, non cross-resistant drug in advanced breast cancer. results from a phase II study. Breast Cancer Res Treat 1996;39:285-91.
7. Brufman G, Haim N, Ben-Baruch N, et al. Second-line chemotherapy with mitoxantrone as a single agent in metastatic breast cancer. J Chemotherapy 1993;5:43-6.
8. Pasterz RB, Buzdar AU, Hortobagyi GN, et al. Mitomycin in metastatic breast cancer refractory to hormonal and combination chemotherapy. Cancer 1985;56:2381-7.
9. Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995;13:2731-6.
10. Regazzoni S, Pesce G, Marini G, et al. Low-dose continuous infusion of 5-fluorouracil for metastatic breast cancer. Ann Oncol 1996;7:807-13.
11. Kraut EH, Balcerzak SP, O'Rourke M, et al. Phase II trial of 9-aminocamptothecin in patients with refractory breast cancer [Abstract]. Proceedings of the American Society of Clinical Oncology 1997;16:620.
12. Cerar D, Cervek J, Cufer T. Salvage chemotherapy with oral etoposide in metastatic breast cancer: preliminary report. Ann Oncol 1992;3(suppl 5):84.
13. Buzdar AU, Hortobagyi GN, Frye D, et al. Second line chemotherapy for metastatic breast cancer including quality of life issues. The Breast 1996;5:312-7.
14. Clark PI, Slevin ML. The clinical pharmacology of etoposide and tenoposide. Clin Pharmacokinet 1987;12:223-52.
15. Schell FC, Yap HY, Hortobagyi GN, et al. Phase II study of VP-16-213 (etoposide) in refractory metastatic breast carcinoma. Cancer Chemother Pharmacol 1982;7:223-5.
16. Dombernowsky P, Nissen NI. Schedule dependency of the anti-leukemic activity of podophylotoxin-derivative VP-16-213 in L1210 leukemia. Acta Pathologica Microbiologia Scandinavia 1973;81(sec A):715-24.
17. Cavalli F, Sonntag RW, Jungi F, et al. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dose schedules. Cancer Treat Rep 1978;62:473-5.
18. Slevin ML, Clark PI, Osborne RJ, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer [Abstract]. Proceedings of the American Society of Clinical Oncology 1986;5:175.
19. Hainsworth JD, Johnson DH, Frazier SR, et al. Chronic daily administration of oral etoposide. a phase I study. J Clin Oncol 1991;7:396-401.
20. Walters R, Theriault R, Wasaff B, et al. A phase II study of oral etoposide (VP-16) in patients with metastatic breast cancer [Abstract]. Proceedings of the Annual Meeting of the American Association for Cancer Research 1994;35:A1356.
21. Falkson G, vanDyk JJ, van Eden EB, et al. A clinical trial of the oral form of 4-demethyl-epipodophyllotoxin-beta-D ethylidene glucoside, VP-16-213. Cancer 1975;35:1141-9.
22. Calvert AH, Lind MJ, Millward MM, et al. Long term etoposide in metastatic breast cancer: clinical and pharmacologic results. Cancer Treat Rev 1993;19(Suppl C):27-33.
23. Palombo H, Estape J, Vinolas N, et al. Chronic oral etoposide in advanced breast cancer. Cancer Chemother Pharmacol 1994;33:527-9.
24. Martin M, Lluch A, Casado A, et al. Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. J Clin Oncol 1994;12:986-91.
25. Neskovic-Konstantinovic ZB, Bosnjak SM, Radulovic SS, et al. Daily oral etoposide in metastatic breast cancer. Anti-Cancer Drugs 1996;7:543-7.
26. Atienza DM, Vogel CL, Trock B, et al. Phase II study of oral etoposide for patients with advanced breast cancer. Cancer 1995;76:2485-90.
27. Botenbal M, Planting AS, Verweij J, et al. Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer. Breast Cancer Res Treat 1995;34: 185-9.